Fulgent Genetics, Inc. (FLGT) Tops Q4 EPS by 87c; Guides

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. CDNS
2. AVGO
3. SPY
4. META
5. JBLU
6. ANT
7. AAPL
8. SSD
9. ARTV
10. AGYS

Go back to Fulgent Genetics, Inc. (FLGT) Tops Q4 EPS by 87c; Guides

Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results

February 23, 2022 4:05 PM EST

Full Year 2021 Total Revenue grows 135% year-over-year to $992.6 million; Q4 Revenue totals $251.7 million Full Year 2021 Core Revenue grows 236% year-over-year to $122.6 million; Q4 Core Revenue grows 234% year-over-year to $40.1 million

TEMPLE CITY, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics, Fulgent, or the Company), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its fourth quarter and full year ended December 31, 2021.

Fourth Quarter 2021 Results:

Revenue of $251.7 million Billable tests delivered... More